Haemonetics Q4 Earnings Exceed Expectations On Volume And Price Benefits

  • Haemonetics Corporation HAE reported fourth-quarter FY23 revenues of $304.42 million, beating the consensus of $289.64 million. Revenues rose 14.9% year over year.
  • The medical products firm reported an adjusted EPS of $0.77, beating the analyst consensus of $0.70.
  • Volume and price benefits and lower restructuring and related spending bolstered quarterly performance. Strength in the Plasma unit, which jumped 31.2% organically Y/Y, also aided Q4 revenues.
  • The adjusted gross margin was 51.8%, down 180 basis points due to inflationary pressures, increased depreciation expense, and foreign exchange.
  • Adjusted operating margin was 17.7%, up 10 basis points Y/Y.
  • The company exited the quarter with cash on hand of $284.5 million on April 1, 2023.
  • “We are outperforming in a challenging economic environment and meeting the needs of our customers while positioning us for future growth and success,” CEO Chris Simon said.
  • FY24 Outlook: HAE expects Adjusted EPS of $3.45 - $3.75, versus the consensus of $3.40.
  • Organic revenue growth is expected to be 5% - 8%, while adjusted operating margin is expected to be 20% - 21%.
  • Price Action: HAE shares closed higher by 2.09% at $83.10 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsEquitiesNewsGuidanceHealth CareMarketsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!